RISPERIDEX 4 MG

Riik: Iisrael

keel: inglise

Allikas: Ministry of Health

Osta kohe

Infovoldik Infovoldik (PIL)
26-03-2019
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
20-08-2020

Toimeaine:

RISPERIDONE

Saadav alates:

DEXCEL PHARMA TECHNOLOGIES LTD

ATC kood:

N05AX08

Ravimvorm:

CAPLETS

Koostis:

RISPERIDONE 4 MG

Manustamisviis:

PER OS

Retsepti tüüp:

Required

Valmistatud:

DEXCEL LTD, ISRAEL

Terapeutiline rühm:

RISPERIDONE

Terapeutiline ala:

RISPERIDONE

Näidustused:

Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years.Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

Loa andmise kuupäev:

2021-05-31

Dokumendid teistes keeltes

Infovoldik Infovoldik araabia 10-11-2020
Infovoldik Infovoldik heebrea 23-05-2019

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu